TP53 and non-small cell lung carcinoma: Additionally, a retrospective study (27) demonstrated that the combination of EGFR-TKI with chemotherapy could provide more survival benefits than EGFR-TKI monotherapy for NSCLC patients with the TP53-EGFR co-mutation.